Rapid and sensitive proximity-based assay for the detection and quantification of DNA binding proteins

• US 20030049625A1
• Filed: 08/13/2001
• Published: 03/13/2003
• Est. Priority Date: 08/13/2001
• Status: Active Grant

• Current Assignee: Saint Louis University
• Original Assignee: Saint Louis University
• Inventors: Heyduk, Tomasz
• Granted Patent: US 6,544,746 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: G01N 33/542 with steric inhibition or signal modification, e.g. fluorescent quenching
• CPC Class Codes: G01N 33/6875 Nucleoproteins

Abstract

Methods to determine the activity of any and all DNA binding factors, proteins or fragments thereof based upon the detection of a change in a luminescence or fluorescence signal are provided. Preferably, a fluorescence donor is attached to a nucleic acid comprising one portion of a DNA binding element and a fluorescence acceptor is attached to a nucleic acid comprising the other portion of the same binding element. Alternatively, a microsphere bead is attached to a nucleic acid comprising one portion of a binding element and a luminescent moiety or fluorochrome is attached to a nucleic acid comprising the other portion of the same binding element. Binding of a DNA binding factor to the nucleic acid components affects a change in luminescence. These methods may also be used to detect mediating analytes, to diagnose diseases and/or screen for drugs that mediate the activity of DNA binding factors.

Claims

1. A method of determining the activity of a DNA binding factor in a sample comprising combining two nucleic acid components with the sample wherein

(a) each nucleic acid component comprises a portion of a DNA binding element wherein the combination of both nucleic acid components comprises a complete DNA binding element,

(b) one nucleic acid component is labeled with a fluorescence donor and the other nucleic acid component is labeled with a fluorescence acceptor, and

(c) the binding of a DNA binding factor or factors contained within the sample to the DNA binding element is detected by a proximity-based luminescence detection method.

2. The method of claim 1 wherein

(a) the DNA binding factor is selected from the group consisting of transcription factor, chromatin remodeling factor and genome maintenance enzyme, and

(b) the proximity-based luminescence detection method is selected from the group consisting of fluorescence resonance energy transfer (“

FRET”

), luminescence resonance energy transfer (“

LRET”

), fluorescence cross-correlation spectroscopy (“

FCCS”

), flow cytometry, scintillation proximity (“

SPA”

), direct quenching, ground-state complex formation, chemiluminescence energy transfer (“

CRET”

), bioluminescence energy transfer (“

BRET”

) and excimer formation.

3. The method of claim 2 wherein the DNA binding factor is a transcription factor.

4. The method of claim 2 wherein the proximity-based luminescence detection method is FRET.

5. The method of any of claims 1-4 wherein the two nucleic acid components are joined by a linker.

7. The method of any of claims 1-4 wherein the nucleic acid components are attached to a solid substrate.

8. A method of detecting enhanceosome proteins in a sample comprising combining a DNA molecule with said sample wherein

(a) the DNA molecule comprises at least two DNA binding elements,

(b) the DNA molecule is labeled at one position with a fluorescence donor and at another position with a fluorescence acceptor,

(c) the binding of one or more enhanceosome proteins to the DNA molecule is detected by a proximity-based luminescence detection method.

6. The method of claim 8 wherein the linker is comprised of spacer 18 phosphoramidate moieties.

9. The method of claim 8 wherein the DNA molecule is attached to a solid substrate.

10. The method of claim 8 or 9 wherein the proximity-based luminescence detection method is selected from the group consisting of fluorescence resonance energy transfer (“

FRET”

), luminescence resonance energy transfer (“

LRET”

), fluorescence cross-correlation spectroscopy (“

FCCS”

), flow cytometry, scintillation proximity (“

SPA”

), direct quenching, ground-state complex formation, chemiluminescence energy transfer (“

CRET”

), bioluminescence energy transfer (“

BRET”

) and excimer formation.

11. The method of claim 10 wherein the proximity-based luminescence detection method is FRET.

12. A method of detecting or quantifying the amount of an analyte in a sample comprising combining two nucleic acid components and at least one DNA binding factor with the sample wherein

(a) each nucleic acid component comprises a portion of a DNA binding element wherein the combination of both nucleic acid components comprises a complete DNA binding element,

(b) one nucleic acid component is labeled with a fluorescence donor and the other nucleic acid component is labeled with a fluorescence acceptor,

(c) the association of the DNA binding factor to the DNA binding element is detected by a proximity-based luminescence detection method, and

(d) the association of the DNA binding factor to the DNA binding element is mediated by the analyte.

13. The method of claim 12 wherein

(a) the DNA binding factor is selected from the group consisting of transcription factor, chromatin remodeling factor and genome maintenance enzyme,

(b) the proximity-based luminescence detection method is selected from the group consisting of fluorescence resonance energy transfer (“

FRET”

), luminescence resonance energy transfer (“

LRET”

), fluorescence cross-correlation spectroscopy (“

FCCS”

), flow cytometry, scintillation proximity (“

SPA”

), direct quenching, ground-state complex formation, chemiluminescence energy transfer (“

CRET”

), bioluminescence energy transfer (“

BRET”

) and excimer formation, and

(c) the analyte is selected from the group consisting of secondary messenger molecule, cellular event, drug, agent, reagent, prospective drug, prospective agent and prospective reagent.

14. The method of claim 13 wherein the DNA binding factor is a genome maintenance enzyme.

15. The method of claim 13 wherein the proximity-based luminescence detection method is FRET.

16. The method of claim 15 wherein the transcription factor is CAP and the analyte is cAMP.

17. The method of any of claims 13-16 wherein the two nucleic acid components are joined by a linker.

18. The method of claim 17 wherein the linker is comprised of spacer 18 phosphoramidate moieties.

19. The method of any of claims 13-16 wherein the nucleic acid components are attached to a solid substrate.

20. A method of detecting or quantifying the amount of multiple different DNA binding factors in a sample comprising combining at least two sets of nucleic acid components with the sample wherein

(a) each nucleic acid component of a set of nucleic acid components comprises a portion of a DNA binding element wherein the combination of both nucleic acid components of said set of nucleic acid components comprises a complete DNA binding element,

(b) one nucleic acid component of a set of nucleic acid components is labeled with a fluorescence donor and the other nucleic acid component of a set of nucleic acid components is labeled with a fluorescence acceptor,

(c) each set of nucleic acid components is labeled with a unique combination of fluorescent donor and acceptor which emits light at a unique wavelength, and

(d) the binding of one or more DNA binding factors contained within the sample to the DNA binding element is detected by a proximity-based luminescence detection method.

21. The method of claim 20 wherein

(a) the DNA binding factors are selected from the group consisting of transcription factor, chromatin remodeling factor and genome maintenance enzyme, and

(b) the proximity-based luminescence detection method is selected from the group consisting of fluorescence resonance energy transfer (“

FRET”

), luminescence resonance energy transfer (“

LRET”

), fluorescence cross-correlation spectroscopy (“

FCCS”

), flow cytometry, scintillation proximity (“

SPA”

), direct quenching, ground-state complex formation, chemiluminescence energy transfer (“

CRET”

), bioluminescence energy transfer (“

BRET”

) and excimer formation.

22. The method of claim 21 wherein the proximity-based luminescence detection method is FRET.

23. A method for diagnosing a disease mediated by a DNA binding factor comprising combining a sample obtained from a subject with at least two nucleic acid components wherein

(a) each nucleic acid component comprises a portion of a DNA binding element wherein the combination of both nucleic acid components comprises a complete DNA binding element,

(b) one nucleic acid component is labeled with a fluorescence donor and the other nucleic acid component is labeled with a fluorescence acceptor,

(c) the sample comprises cellular extracts, and

(d) the binding of a DNA binding factor or factors contained within the sample to the DNA binding element is detected by a proximity-based luminescence detection method.

24. The method of claim 23 wherein

(a) the DNA binding factor is selected from the group consisting of transcription factor, chromatin remodeling factor and genome maintenance enzyme, and

(b) the proximity-based luminescence detection method is selected from the group consisting of fluorescence resonance energy transfer (“

FRET”

), luminescence resonance energy transfer (“

LRET”

), fluorescence cross-correlation spectroscopy (“

FCCS”

), flow cytometry, scintillation proximity (“

SPA”

), direct quenching, ground-state complex formation, chemiluminescence energy transfer (“

CRET”

), bioluminescence energy transfer (“

BRET”

) and excimer formation.

25. The method of claim 24 wherein the DNA binding factor is a genome maintenance enzyme.

26. The method of claim 25 wherein the genome maintenance enzyme is p53.

27. The method of claim 24 wherein the proximity-based luminescence detection method is FRET.

28. The method of claim 24 wherein the subject is a human patient.

29. The method of claim 24 wherein the human patient suffers from a type of cancer or disease of genome instability.

30. A method of determining the activity of a DNA binding factor in a sample comprising combining two nucleic acid components with the sample wherein

(a) each nucleic acid component comprises a portion of a DNA binding element wherein the combination of both nucleic acid components comprises a complete DNA binding element,

(b) one nucleic acid component is labeled with an enzyme, cofactor or catalyst and the other nucleic acid component is labeled with a chemiluminescent substrate or a colorimetric substrate, and

(c) the binding of a DNA binding factor or factors contained within the sample to the DNA binding element is determined by the detection of a change in luminescence or color.

31. An array comprising multiple sets of nucleic acid constructs wherein

(a) each nucleic acid component of a set of nucleic acid components comprises a portion of a DNA binding element wherein the combination of both nucleic acid components of said set of nucleic acid components comprises a complete DNA binding element, and

(b) one nucleic acid component of a set of nucleic acid components is labeled with a fluorescence donor and the other nucleic acid component of a set of nucleic acid components is labeled with a fluorescence acceptor,

32. The array of claim 31 wherein said sets of nucleic acid constructs are affixed to a solid substrate.

33. The array of claim 31 or 32 wherein both nucleic acid components of a set of nucleic acid components are connected by a linker

34. A method of determining the activity of a DNA binding factor in a sample comprising combining two nucleic acid components with the sample wherein

(a) each nucleic acid component comprises a portion of a DNA binding element wherein the combination of both nucleic acid components comprises a complete DNA binding element,

(b) one nucleic acid component is linked to a microsphere and the other nucleic acid component is labeled with a fluorochrome, and

(c) the binding of a DNA binding factor or factors contained within the sample to the DNA binding element is detected by flow cytometry.

35. A method of determining the affinity of a DNA binding factor for a variant nucleic acid sequence comprising combining the variant nucleic acid sequence with the DNA binding factor and two nucleic acid components wherein

(a) each nucleic acid component comprises a portion of a DNA binding element wherein the combination of both nucleic acid components comprises a complete DNA binding element,

(b) one nucleic acid component is labeled with a fluorescence donor and the other nucleic acid component is labeled with a fluorescence acceptor, and

(c) the binding of a DNA binding factor or factors contained within the sample to the DNA binding element is detected by a proximity-based luminescence detection method.

36. A method of determining the activity of a DNA binding factor in a sample comprising combining two nucleic acid components with the sample wherein

(a) each nucleic acid component comprises a portion of a DNA binding element wherein the combination of both nucleic acid components comprises a complete DNA binding element,

(b) one nucleic acid component is linked to a microsphere that is imbued with a scintillant and the other nucleic acid component is labeled with a radioisotope, and

(c) the binding of a DNA binding factor or factors contained within the sample to the DNA binding element is detected by a scintillation proximity assay.